STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom

FDA’s hiring spree hits bottleneck, mice with half-human brains, and more biotech news Adobe Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The FDA’s new hiring push is hitting some complications. Also, a startup is bringing a psychedelic-esque drug to Parkinson’s, and we’ve got mice with human-esque brains. This WIRED video on Stone Age AI slop is on in the background for me right now, and I enjoy this quote from anthropologist Agustín Fuentes: “Why invent garbage when you actually have science?” STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter. National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.